|Bid||37.00 x 1400|
|Ask||0.00 x 2200|
|Day's Range||39.94 - 40.71|
|52 Week Range||31.99 - 41.78|
|Beta (3Y Monthly)||0.64|
|PE Ratio (TTM)||38.55|
|Forward Dividend & Yield||1.40 (3.42%)|
|1y Target Est||42.66|
Early losses in chip stocks and retail names sent stocks to a weak open Friday, but Viacom rose on earnings, and PG&E received some relief.
Pascal Soriot became the CEO of AstraZeneca PLC (LON:AZN) in 2012. First, this article will compare CEO compensation with compensation at other large companies. Next, we’ll consider growth that the Read More...
FDA provides updates on Merck (MRK), AstraZeneca (AZN) and Roche (RHHBY) for their cancer drugs. Bayer (BAYRY) reports strong third-quarter results.
On Friday, the company said Imfinzi, its key lung cancer drug, had failed to deliver significant survival rates in late-stage, non-small cell lung cancer when used in combination with another of its immuno-oncology treatments. Rewind four years, and immuno-oncology – which enhances the body’s own ability to fight cancer – was a central pillar of Soriot’s defense. Concern about this pairing's performance in tests is one reason why it has taken until this year for AstraZeneca shares to climb above the 55 pounds-a-share proposal from Pfizer and stay there.
The cocktail of Imfinzi and tremelimumab didn’t improve patients’ overall survival in non-small-cell lung cancer compared with standard chemotherapy alone, the company said Friday in a statement. The results didn’t meet statistical significance, and the data support further analysis, Astra said. Imfinzi is one of a number of new drugs, along with Lynparza for cancer and Farxiga for diabetes, that Astra is looking to for growth in the coming years as it pares away fading blockbusters.
lung cancer treatment has confirmed the treatment fails to deliver the improvements to survival rates that had been hoped for. AstraZeneca had hoped the medicine, whichis called Imfinzi, would eventually be adopted as a first line treatment for non-small cell lung cancer. when an earlier version of the study, known as Mystic, showed the treatment had failed to meet its “endpoints” for progression-free survival — the length of time for which people go without their cancer worsening — in previously-untreated patients with Stage IV of the cancer.
AstraZeneca stock jumped Tuesday after the U.K.-based pharma giant said it would sell the U.S. rights to infant respiratory drug for $1.5 billion.
AstraZeneca (AZN) to sell U.S. rights of Synagis to Sobi for an upfront consideration of $1.5 billion as it streamlines its portfolio
PARP inhibitor makers get a boost following priority review for AstraZeneca???s (AZN) label expansion application for Lynparza as a first-line maintenance treatment for ovarian cancer.
Does AstraZeneca plc (ADR) (NYSE:AZN) represent a good buying opportunity at the moment? Let’s briefly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and invest millions of dollars on research activities, so it is no wonder why they tend to generate millions in profits […]
AstraZeneca (AZN) and partner Merck's sNDA looking for label expansion of Lynparza in the first-line setting gets FDA's priority review.
AstraZeneca's deal to sell the U.S. rights to Synagis to a Swedish biopharmaceutical company is expected to be finalized early next year.
Sobi, officially Swedish Orphan Biovitrum AB, also gained the right to share the U.S. profits and losses on a potential new medicine, which Astra is developing with Sanofi, that targets the same lung virus Synagis treats, the Cambridge, England-based company said in a statement. Chief Executive Officer Pascal Soriot has been paring back Astra’s portfolio, selling the rights to fading blockbusters such as Nexium for reflux as a new crop emerges, led by Imfinzi and other cancer drugs.
AG said earnings fell sharply in the third quarter, in part as a result of a one-off gain booked in the prior year, while the number of glyphosate-related lawsuits it faces rose. Aftertax profit at the German chemical maker was 2.89 billion euros ($3.26 billion) compared with EUR3.88 billion a year earlier. DCC PLC said pretax profit in the first half of fiscal 2019 rose 17% and it continues to expect the full year to see more profit growth.
AstraZeneca has taken another step to refocus on priority drugs by selling U.S. rights to a treatment for infant lung infections to Swedish Orphan Biovitrum for an upfront fee of $1.5 billion. Around 130 AstraZeneca staff will transfer to Sobi as the Swedish company, widely known as Sobi, takes over marketing of the treatment Synagis in the United States.
AstraZeneca took another step to refocus its portfolio on priority projects on Tuesday by selling U.S. rights to a treatment for a serious infant lung infection to Swedish Orphan Biovitrum for an upfront fee of $1.5 billion. Around 130 AstraZeneca staff will transfer to Sobi as the Swedish company, widely known as Sobi, takes over marketing of the drug Synagis in the United States. Sobi also gets the right to participate in AstraZeneca's share of U.S. profits and losses in a follow-on drug for respiratory syncytial virus, called MEDI8897, which AstraZeneca is developing with Sanofi, the companies said.
Approval would expand use of AstraZeneca and MSD’s LYNPARZA to patients in the 1st-line setting following platinum-based chemotherapy
Fewer MACE events observed with FARXIGA vs. placebo, but this finding did not reach statistical significance
The biggest clinical trial so far to assess a new class of diabetes pills shows that AstraZeneca's Farxiga can prevent heart failure and cut the risk of kidney problems in a broad range of patients. Diabetics are at increased risk of heart problems, making the CV profile of drugs to treat the condition an important focus for doctors and patients.
has markedly reduced the chances of diabetic patients being hospitalised with heart failure, a condition associated with type 2 diabetes. The findings, from a large clinical trial, represent a significant boost for the Anglo-Swedish drugmaker which is striving to meet ambitious revenue targets. Cardio-vascular complications are common in people who contract type 2 diabetes, which has become a major burden on health systems worldwide.
GW Pharmaceuticals (GWPH) is a developer of plant-derived cannabinoid therapeutics. GW Pharmaceuticals reported EPS of -$1.26 on revenue of $3.46 million in the third quarter, reflecting a 10.2% year-over-year revenue rise in the quarter.
Lilly (LLY) and AstraZeneca (AZN) report third-quarter results. Pfizer (PFE) gains FDA approval for a new cancer medicine.
NEW YORK, NY / ACCESSWIRE / November 9, 2018 / U.S. stocks retreated on Thursday after the Fed left interest rates unchanged and signaled that it would continue to tighten monetary policy at a gradual pace. Charlie Ripley, senior investment strategist at Allianz Investment Management said that, “With no press conference or expectation for policy change, most market participants viewed the November FOMC meeting as more of a non-event. “With only minimal changes to the statement the Fed is remaining vague about policy changes going forward and likely giving the committee more optionality in a changing market environment,” he added.
This article is from today’s FT Opinion email. Sign up to receive a daily digest of the big issues straight to your inbox. Does Europe have a strategy for coping with Donald Trump? His “America First” ...
AstraZeneca stock broke out Thursday after the pharma reported sales growth, claiming the quarter to be the beginning of continued growth.